These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21383688)

  • 1. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
    Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
    Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.
    Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y
    Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
    Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
    Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
    Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.
    Lee J; Jiffar T; Kupferman ME
    PLoS One; 2012; 7(1):e30246. PubMed ID: 22276165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
    Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
    Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
    Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
    Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma.
    Ogawa T; Ogawa K; Shiga K; Furukawa T; Nagase H; Hashimoto S; Kobayashi T; Horii A
    Eur Arch Otorhinolaryngol; 2010 Oct; 267(10):1599-606. PubMed ID: 20443017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
    Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
    Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
    Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
    PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
    Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
    Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
    Liu CJ; Chang WJ; Chen CY; Sun FJ; Cheng HW; Chen TY; Lin SC; Li WC
    Oncotarget; 2015 Oct; 6(30):29268-84. PubMed ID: 26337468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells.
    Steinbichler TB; Metzler V; Pritz C; Riechelmann H; Dudas J
    Oncotarget; 2016 Jan; 7(3):2508-18. PubMed ID: 26497215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 20. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
    Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
    Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.